A Proof-of-Concept Study to Assess the Efficacy Safety and Tolerability of itepekimab (anti-IL-33 mAb) in Participants with Non-Cystic Fibrosis Bronchiectasis

Brief description of study

This study aims to evaluate the safety, efficacy, and tolerability of itepekimab in patients with bronchiectasis, in addition to their current treatment regimen, which may include bronchodilators, inhaled corticosteroids, mucolytics, and/or maintenance antibiotics. The main objective is to determine if itepekimab can reduce the frequency of pulmonary exacerbations (such as increased cough, sputum production, and shortness of breath) and improve the signs and symptoms of bronchiectasis. The study will also explore how itepekimab works in the body and identify any potential side effects.

The study will compare itepekimab with a placebo to assess its effectiveness and safety in reducing bronchiectasis-related flare-ups and improving respiratory function. Results will help determine if itepekimab offers a more effective treatment option for bronchiectasis, providing valuable insights into its potential benefits and risks. By participating, patients will contribute to the understanding of itepekimab as a potential new treatment for bronchiectasis.


Clinical Study Identifier: s23-01063
ClinicalTrials.gov Identifier: NCT06280391
Principal Investigator: Doreen J Addrizzo-Harris.
Other Investigator: Ashwin Basavaraj.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.